Making Distributed Manufacturing Work Beyond Theory

In this segment of During Cell & Gene Live, “Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?,” experts Emily Moran, Founder, 3LB Consulting, LLC and Sugu Patro, Ph.D., Senior Vice President Global Process Development at Kite, a Gilead Company explored the operational realities behind distributed manufacturing in cell and gene therapy, stating that success depends less on the concept itself and more on orchestration, harmonization, and centralized process control across sites. They highlighted the importance of strong project management, supply chain and logistics planning, product comparability, and governance systems capable of ensuring every site consistently manufactures the same high-quality product despite regional variability and evolving regulatory expectations.